Syneos Health (NASDAQ:SYNH) updated its FY 2021
Pre-Market earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.09-4.38 for the period, compared to the Thomson Reuters consensus estimate of $4.18. The company issued revenue guidance of $5.125-5.325 billion, compared to the consensus revenue estimate of $5.13 billion.Syneos Health also updated its FY 2020
Pre-Market guidance to 3.33-3.46 EPS.
SYNH has been the topic of several analyst reports. Smith Barney Citigroup boosted their price target on shares of Syneos Health from $75.00 to $80.00 in a research report on Wednesday, December 9th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on shares of Syneos Health from $75.00 to $80.00 in a report on Wednesday, December 9th. BidaskClub raised shares of Syneos Health from a hold rating to a buy rating in a report on Thursday, January 7th. Mizuho increased their target price on shares of Syneos Health from $65.00 to $72.00 and gave the stock a buy rating in a research report on Wednesday, December 9th. Finally, JPMorgan Chase & Co. increased their price target on shares of Syneos Health from $80.00 to $85.00 and gave the stock an overweight rating in a research report on Wednesday, December 9th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $72.07.
SYNH stock opened at $74.61 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.12 and a quick ratio of 1.12. Syneos Health has a one year low of $30.02 and a one year high of $75.39. The stock has a market cap of $7.75 billion, a PE ratio of 41.92 and a beta of 1.74. The firm has a 50 day simple moving average of $67.58 and a two-hundred day simple moving average of $61.43.
In other Syneos Health news, insider Michelle Keefe sold 800 shares of the company’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $62.65, for a total value of $50,120.00. Following the completion of the transaction, the insider now directly owns 49,643 shares in the company, valued at approximately $3,110,133.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas H. Lee Advisors, Llc sold 627 shares of the company’s stock in a transaction on Thursday, December 3rd. The stock was sold at an average price of $61.28, for a total transaction of $38,422.56. The disclosure for this sale can be found here. Insiders sold a total of 3,242,420 shares of company stock valued at $198,800,919 in the last ninety days. 0.44% of the stock is owned by corporate insiders.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: What does it mean to hold a stock in street name?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.